Arbutus Biopharma Corp. (ABUS) is gearing up for a high-stakes year ahead on the legal front as it intensifies efforts to defend and enforce its proprietary lipid nanoparticle technology.
The lipid nanoparticle (LNP) technology, developed by Arbutus and Genevant Sciences Ltd., relies on microscopic particles built from four carefully selected types of fat-like molecules, called lipids, to shelter and protect mRNA molecules and help deliver them safely to target cells in the body, where they can enter the cells. Without this crucial delivery technology, mRNA would quickly degrade in the body and be ineffective.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.